Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping The Future Of Advanced Endometrial Cancer Therapeutics Space Delveinsight

Stuti Mahajan, consulting manager at DelveInsight, said that advanced endometrial cancer is a challenging, often recurrent or metastatic form of disease where treatment innovation is reshaping the therapeutic landscape. The market is gaining momentum as immunotherapies, targeted agents, and ADCs emerge, broadening treatment options while driving a more competitive and increasingly biomarker-driven market.

Recent Developments in Advanced Endometrial Cancer Treatment Space

• In August 2026, Faeth Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to the combination of sapanisertib and serabelisib (PIKTOR) with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration and who have previously been treated with platinum-based chemotherapy and an immune checkpoint inhibitor (ICI).
• In May 2026, Merck announced the pivotal Phase III TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC) being developed in collaboration with Kelun-Biotech, met its primary endpoints of overall survival (OS) and progression-free survival (PFS) in certain patients with advanced or recurrent endometrial cancer.
• In April 2026, BioNTech SE announced positive results from the primary analysis of a Phase II cohort evaluating trastuzumab pamirtecan (BNT323/DB-1303) in patients with HER2-expressing, advanced endometrial cancer whose disease progressed on or after first-line chemotherapy with or without prior checkpoint inhibitor treatment.
• In February 2026, Sensei Biotherapeutics, Inc. announced that it has acquired Faeth Therapeutics Inc. The acquisition brings Faeth's lead asset PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, into Sensei's pipeline.
• In October 2025, Genmab A/S announced updated data from cohort B2 of the Phase I/II RAINFOLTM-01 trial evaluating rinatabart sesutecan (Rina-S®). The study showed that at a median study follow-up of one year, treatment with Rina-S 100 mg/m2 every 3 weeks (Q3W) resulted in a 50.0% confirmed objective response rate (ORR), including two complete responses (CR), in heavily pretreated patients with advanced endometrial cancer (EC) who had progressed following platinum-based chemotherapy and an immune checkpoint inhibitor.
• In August 2025, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to Rina-S for the treatment of adult patients with recurrent or progressive EC who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapy.

Scope of the Advanced Endometrial Cancer Pipeline Report

• Coverage: Global
• Advanced Endometrial Cancer Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Advanced Endometrial Cancer Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Advanced Endometrial Cancer Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Advanced Endometrial Cancer Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Advanced Endometrial Cancer Therapeutics Assessment By Mechanism of Action: PD-L1, VEGFR Inhibitors, XPO1 inhibition, DNA topoisomerase I inhibitors, Programmed cell death 1 receptor antagonists, Autologous tumor-infiltrating lymphocyte (TIL) replacement, NF-E2-related factor 2 stimulants, NF-kappa B inhibitors, and others
• Key Advanced Endometrial Cancer Companies: Pfizer, Genmab, Incyte Corporation, MacroGenics, Huabo Biopharm Co., Ltd., BioMimetix JV, LLC, Iovance Biotherapeutics, Inc., Karyopharm Therapeutics Inc., Evergreen Therapeutics, Inc., BioNTech SE, Outpace Bio, Tarapeutics Science Inc., and others.
• Key Advanced Endometrial Cancer Pipeline Therapies: PF-08634404, Rinatabart sesutecan, Retifanlimab, HB0025, BMX-001 + Paclitaxel, Lifileucel, Selinexor, EG-007, BNT329, OPB-201, TR115, and others.

Advanced Endometrial Cancer News

Table of Contents

1.	Advanced Endometrial Cancer Pipeline Report Introduction
2.	Advanced Endometrial Cancer Pipeline Report Executive Summary
3.	Advanced Endometrial Cancer Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Advanced Endometrial Cancer Clinical Trial Therapeutics
6.	Advanced Endometrial Cancer Pipeline: Late-Stage Products (Pre-registration)
7.	Advanced Endometrial Cancer Pipeline: Late-Stage Products (Phase III)
8.	Advanced Endometrial Cancer Pipeline: Mid-Stage Products (Phase II)
9.	Advanced Endometrial Cancer Pipeline: Early-Stage Products (Phase I)
10.	Advanced Endometrial Cancer Pipeline Therapeutics Assessment
11.	Inactive Products in the Advanced Endometrial Cancer Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Advanced Endometrial Cancer Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the advanced endometrial cancer clinical trials, reach out @ Advanced Endometrial Cancer Medication

Related Reports

Endometrial Cancer Market

Advanced Endometrial Cancer Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometrial cancer companies, including Merck, Karyopharm Therapeutics, AstraZeneca, Daiichi Sankyo, Faeth Therapeutics, Hoffmann-La Roche, Iovance Biotherapeutics, and others.

Endometrial Cancer Clinical Trial Analysis

Endometrial Cancer Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometrial cancer companies, including Carisma Therapeutics, Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Chimerix, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, among others.

Endometriosis Market

Endometriosis Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key endometriosis companies, including Mitsubishi Tanabe Pharma America, Ferring Pharmaceuticals, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, SWK, Enteris BioPharma, Bayer, Hope Medicine, Organon, and others.

Endometriosis Clinical Trial Analysis

Endometriosis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Hope Medicine (Nanjing) Co., Ltd, TiumBio, EpicentRx, Ferring Pharmaceuticals, Gesynta Pharma, VaRi Bioscience, Viramal, Tanabe Pharma Corporation, Gynica, Absci Corp, and others.

Endometriosis Pain Market

Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve .

CONTACT: Contact Us Shruti Thakur... +14699457679